• Explore /
  • Poster
  • / Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.

Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.

Abstract Poster

Authors

Andrea Apolo

Andrea B. Apolo

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Andrea B. Apolo , Jeffrey R. Infante , Omid Hamid , Manish R. Patel , Ding Wang , Karen Kelly , Anthony E. Mega , Carolyn D. Britten , Alain C. Mita , Alain Ravaud , Jean-Marie Cuillerot , Anja von Heydebreck , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 367)

DOI

10.1200/jco.2016.34.2_suppl.367

Abstract #

367

Poster Bd #

F2

Abstract Disclosures

Similar Posters

First Author: Andrea B. Apolo

First Author: Manish R. Patel

First Author: Hyun Cheol Chung

First Author: Andrea B. Apolo